GlassScriptPhysician profile
James P Corcoran
NPI 1730128091
$2,117.87
in general payments reported to CMS, 2019-2025
31 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $112 · 2021: $94.75 · 2022: $451 · 2023: $516 · 2024: $347 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.88 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Amgen INC. | $216.59 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $167.98 | 2019-2025 | Veozah |
| Pfizer INC. | $155.97 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.59 | 2019-2023 | Jardiance |
| Abbott Laboratories | $112.67 | 2022-2025 | Proclaim, Freestyle Libre 3, Octrode |
| Novo Nordisk INC | $86.69 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $73.59 | 2022-2023 | |
| Allergan, INC. | $59.98 | 2019 | |
| Lilly USA, LLC | $49.12 | 2022 | |
| Radius Health, INC. | $48.37 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $43.04 | 2024-2025 | Airsupra, Breztri |
| Esperion Therapeutics, INC. | $38.30 | 2020-2023 | Nexletol |
| Phathom Pharmaceuticals, INC. | $37.59 | 2023-2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $35.38 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $27.32 | 2022-2023 | Quviviq |
| Verity Pharmaceuticals INC. | $25.17 | 2025 | Tlando |
| Merck Sharp & Dohme LLC | $24.80 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $23.46 | 2025 | Gemtesa |
| Teleflex LLC | $21.97 | 2023 | Urolift |
| Aimmune Therapeutics, INC. | $21.91 | 2024 | |
| Tolmar, INC. | $20.06 | 2025 | Jatenzo |
| Paratek Pharmaceuticals, INC. | $18.81 | 2025 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $16.31 | 2019 | |
| Exact Sciences Corporation | $16.15 | 2025 | Cologuard Collection Kit |
| Medtronic USA, INC. | $16.06 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.89 | 2020 | |
| Phadia US INC. | $14.85 | 2024 | Immunocap |
| Medtronic, INC. | $14.66 | 2023 | Micra |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Antares Pharma, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Corcoran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.